{"organizations": [], "uuid": "47f3632cf73b0416506855d261e15f03643f695e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180301.html", "section_title": "Archive News &amp; Video for Thursday, 01 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ascendis-health-hy-heps-rises-laun/brief-ascendis-health-hy-heps-rises-launches-strategic-review-idUSFWN1QJ01B", "country": "US", "domain_rank": 408, "title": "Ascendis Health HY HEPS Rises, Launches Strategic Review", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T14:06:00.000+02:00", "replies_count": 0, "uuid": "47f3632cf73b0416506855d261e15f03643f695e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ascendis-health-hy-heps-rises-laun/brief-ascendis-health-hy-heps-rises-launches-strategic-review-idUSFWN1QJ01B", "ord_in_thread": 0, "title": "Ascendis Health HY HEPS Rises, Launches Strategic Review", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - ascendis health ltd", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1 (Reuters) - Ascendis Health Ltd:\n* HY ‍NORMALISED HEPS UP 7% TO 75.8 CENTS​ * ‍DIRECTORS HAVE ELECTED NOT TO DECLARE AN INTERIM DIVIDEND AND TO RETAIN CASH TO SETTLE DEBT OBLIGATIONS​\n* ‍TARGETING TO ACCELERATE SYNERGY SAVINGS IN NEXT 12 TO 18 MONTHS, MAINLY IN SOUTH AFRICAN PHARMA AND MEDICAL DEVICES BUSINESSES​\n* ‍TARGETING TO IMPROVE EBITDA MARGIN TO 17% - 18% IN SHORT TO MEDIUM TERM​\n* ‍PROJECTS UNDERWAY TO OPTIMISE INVENTORY LEVELS IN PHARMA-MED AND CONSUMER BRANDS SEGMENTS\n* ‍PROJECTS UNDERWAY TO IMPROVE DEBT COLLECTION FROM PRIVATE SECTOR AND GOVERNMENT DEBTORS IN PHARMA-MED​\n* ‍STRATEGIC BUSINESS REVIEW HAS BEEN INITIATED TO CREATE A“SUSTAINABLE MARKET POSITION” FOR CO AND TO ACCELERATE ORGANIC GROWTH​\n* ‍REVIEW IS EXPECTED TO BE COMPLETED LATE IN 2018 FINANCIAL YEAR​ Source text for Eikon:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T14:06:00.000+02:00", "crawled": "2018-03-02T20:24:49.045+02:00", "highlightTitle": ""}